GALT financials

Galectin Therapeutics (GALT) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.

GALT income statement, yearly

YearRevenueGross profitOperating incomeNet incomeEPS
2025––-$20.09M-$30.97M-0.48
2024––-$42.43M-$47.20M-0.76
2023––-$38.07M-$44.80M-0.74
2022––-$38.35M-$38.87M-0.65
2021––-$30.18M-$30.70M-0.52
2020––-$23.44M-$23.60M-0.41